Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Alendronate Sodium Clear all
Completed Phase 4 Interventional

The Forteo Alendronate Comparator Trial

NCT02416271
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D, Placebo-Oral, Placebo-SC
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
15
States / cities
Mobile, Alabama • Tustin, California • Lakewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis

NCT00005006
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid Hormone, Alendronate, Teriparatide
Drug
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2006
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Renal Osteodystrophy: An Individual Management Approach

NCT02440581
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Alendronate, Teriparatide, Cinacalcet
Drug
Lead sponsor
Hartmut Malluche, MD
Other
Eligibility
21 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bone Loss in Premenopausal Women With Depression

NCT00006180
View directory record Official record
Conditions
Depression, Healthy, Osteopenia, Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 45 Years · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Texture Analysis for Postmenopausal Osteoporosis

NCT00145977
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Alendronate, Calcium Citrate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Early Phase 1 Interventional

64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy

NCT03542695
View directory record Official record
Conditions
Breast Carcinoma, Calcification
Interventions
Computed Tomography, Copper Cu-64-DOTA-alendronate, Pharmacokinetic Study, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 26, 2026, 2:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Glucocorticoids Promote Osteoclast Survival

NCT00572299
View directory record Official record
Conditions
Osteoporosis
Interventions
alendronate
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Sep 26, 2026, 2:59 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Bisphosphonates for Breast Cancer

NCT02781805
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Alendronate
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients

NCT00061256
View directory record Official record
Conditions
HIV Infections
Interventions
Alendronate, Calcium carbonate, Vitamin D
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
25 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional

Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)

NCT00177619
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Alendronate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids

NCT03197623
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Osteonecrosis
Interventions
LLP2A-ALENDRONATE, Placebo
Drug
Lead sponsor
Nancy E. Lane, MD
Other
Eligibility
20 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Cypress, California • Walnut Creek, California • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Sep 26, 2026, 2:59 AM EDT
Completed No phase listed Observational Results available

Alendronate in Juvenile Osteoporosis

NCT00920075
View directory record Official record
Conditions
Juvenile Osteoporosis, Low Bone Density, Fractures
Interventions
Alendronate (Fosamax)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
8 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 26, 2026, 2:59 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Cyclic Versus Daily Teriparatide on Bone Mass

NCT00668941
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 26, 2026, 2:59 AM EDT
Recruiting Phase 2 Interventional

Small Trial of Alendronate Impact on the Reservoir of HIV

NCT07216794
View directory record Official record
Conditions
HIV
Interventions
Alendronate, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
View directory record Official record
Conditions
Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
alendronate sodium, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis

NCT00010439
View directory record Official record
Conditions
Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 14 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

NCT00005005
View directory record Official record
Conditions
Osteoporosis
Interventions
PTH, Alendronate
Drug
Lead sponsor
Dennis Black
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
4
States / cities
Bangor, Maine • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Secondary Prevention of Osteoporosis

NCT00421343
View directory record Official record
Conditions
Osteoporosis
Interventions
alendronate with cholecalciferol, calcium carbonate with cholecalciferol, Falls prevention measures
Drug · Behavioral
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome

NCT00001728
View directory record Official record
Conditions
Polyostotic Fibrous Dysplasia
Interventions
Fosamax (Alendronate)
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Hialeah, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

NCT03396315
View directory record Official record
Conditions
IOP, Osteoporosis
Interventions
Alendronate, Zoledronic Acid
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 26, 2026, 2:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

NCT00297830
View directory record Official record
Conditions
Heart Transplantation, Liver Transplantation, Bone Resorption
Interventions
Zoledronic acid, Alendronate, Placebo Zoledronic Acid, Placebo Alendronate
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 26, 2026, 2:59 AM EDT
Withdrawn Phase 4 Interventional

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

NCT00359385
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
Alendronate 70mg weekly
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 26, 2026, 2:59 AM EDT